Key result
Point-of-care hs-cTnI testing successfully deploys across ~130 instruments in a regional health network.
Why the study?
Although cardiac troponin testing on point of care devices had been available in Western Australia for several years, the existing assays were not considered high sensitivity, prompting the evaluation and statewide implementation of new high-sensitivity troponin I point of care tests.
Answers are grounded in this paper and cite their sources.
Describes the evaluation and state-wide implementation of point-of-care high-sensitivity troponin I testing across 130 instruments to support rapid chest pain assessment in Western Australia.
Point of care (POC) testing is an important part of frontline health care in Western Australia (WA), with testing performed by clinical staff in a variety of urgent care settings. Cardiac troponin testing on POC devices has been available for several years, however the assays on POC devices were not considered high sensitivity. In 2025, the PathWest POC department evaluated new to market high sensitivity troponin I (hsTnI) tests on four POC devices, and proceeded with a roll-out out of hsTnI on the existing fleet of Abbott iSTAT instruments. The implementation of the new hsTnI to replace existing cardiac TnI testing across WA was a large project, given the extensive regional area of the state, an area of 2.5 million square kilometres. Evaluation of the iSTAT hsTnI cartridge was performed, including interference testing, and a managed roll-out of the test across 130 ISTAT instruments in WA was undertaken.
No takes yet. Share an insight, caveat, or question.
Byrnes et al. (2026) studied Chest pain. High-sensitivity troponin I (hsTnI) point of care testing (Abbott iSTAT) vs. Existing cardiac troponin I (TnI) testing was evaluated. High-sensitivity troponin I point-of-care testing was evaluated on four devices and rolled out across 130 Abbott iSTAT instruments in Western Australia.
Synapse has enriched 10 related papers. Consider them for comparative context: